Intratumoral Cancer Therapies Global Market Is Expected To Grow At A Rate Of 12% Through 2023 – 2027
2 Jun, 2023
The global intratumoral cancer therapies market size is expected to grow from $109.66 billion in 2022 to $124.82 billion in 2023 at a compound annual growth rate (CAGR) of 13.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global intratumoral cancer therapies market size is expected to reach $197.86 billion in 2027 at a CAGR of 12.2%.
Global Intratumoral Cancer Therapies Market Key Driver
The rising incidence of cancer is projected to boost the intratumoral cancer treatments market ahead. Cancer is a condition in which a person's cells grow out of control and spread to other parts of the body. As the global prevalence of cancer continues to climb, there is an increasing demand for effective and tailored cancer medicines. Intratumoral cancer medicines are utilised in cancer diagnosis and treatment to prevent off-target toxicities, dose-limiting toxicities, and unfavourable effects owing to immune activation in cancer patients.
Get a sample of the global intratumoral cancer therapies market reportGlobal Intratumoral Cancer Therapies Market Segments
The global intratumoral cancer therapies market is segmented:
1) By Technology: Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Cytokines
2) By Application: Lung Cancer, Breast Cancer, Malenoma, Prostate Cancer, Head and Neck Cancer, Other Applications
3) By End Users: Hospitals, Cancer Research Centres, Clinics
4) By Geography: The regions covered in the intratumoral cancer therapies market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global intratumoral cancer therapies market.
Major Intratumoral Cancer Therapies Industry Players
Amgen Inc., AstraZeneca Plc., Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Celgene Corporation, Takeda Pharmaceutical Company Ltd., GlaxoSmithKline PLC., Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc.
Get the full global intratumoral cancer therapies market report
Intratumoral Cancer Therapies Market Overview
Intratumoral cancer therapies refer to treatments that are directly injected or applied to a tumor. These therapies are specifically designed to target tumor cells and can be used with other cancer treatments, such as chemotherapy and radiation therapy.
Intratumoral Cancer Therapies Global Market Report 2023 provides data on the global intratumoral cancer therapies market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The intratumoral cancer therapies market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.